loader from loading.io

VR-Based Vision Therapy for Lazy Eye and Binocular Vision Disorders with Ben Backus and James Blaha Vivid Vision

Empowered Patient Podcast

Release Date: 01/15/2026

AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics TRANSCRIPT show art AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics TRANSCRIPT

Empowered Patient Podcast

Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc.,  has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic test, CNSide, can detect cancer cells in cerebrospinal fluid, addressing the shortcomings of imaging and outdated standard-of-care practices. Using AI and advanced data analytics, their lead drug candidate is uniquely suited for treating CNS cancers because its safety at high doses enables the...

info_outline
AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics show art AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics

Empowered Patient Podcast

Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc.,  has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic test, CNSide, can detect cancer cells in cerebrospinal fluid, addressing the shortcomings of imaging and outdated standard-of-care practices. Using AI and advanced data analytics, their lead drug candidate is uniquely suited for treating CNS cancers because its safety at high doses enables the...

info_outline
Proactive Care and Digital Tools Are Transforming Senior Living Facilities with Kristy Yoskey PointClickCare TRANSCRIPT show art Proactive Care and Digital Tools Are Transforming Senior Living Facilities with Kristy Yoskey PointClickCare TRANSCRIPT

Empowered Patient Podcast

Kristy Yoskey, VP and Market Leader at PointClickCare, sees the evolution of demands of those living in senior living facilities from expecting basic housing to a desire for lifestyle choices, health services, and engagement in meaningful activities. On the facilities side, there is a shift from reactive to proactive care, where technology is used to monitor residents, identify behavioral changes, support clinical decision-making, and intervene early to prevent adverse events. In addition, the complexity of resident care is increasing, blurring the line between hospitality and healthcare and...

info_outline
Proactive Care and Digital Tools Are Transforming Senior Living Facilities with Kristy Yoskey PointClickCare show art Proactive Care and Digital Tools Are Transforming Senior Living Facilities with Kristy Yoskey PointClickCare

Empowered Patient Podcast

Kristy Yoskey, VP and Market Leader at PointClickCare, sees the evolution of demands of those living in senior living facilities from expecting basic housing to a desire for lifestyle choices, health services, and engagement in meaningful activities. On the facilities side, there is a shift from reactive to proactive care, where technology is used to monitor residents, identify behavioral changes, support clinical decision-making, and intervene early to prevent adverse events. In addition, the complexity of resident care is increasing, blurring the line between hospitality and healthcare and...

info_outline
Using Behavioral Science to Expand Clinical Trial Participation and Patient Engagement with Sarah Smith Oracle Life Sciences TRANSCRIPT show art Using Behavioral Science to Expand Clinical Trial Participation and Patient Engagement with Sarah Smith Oracle Life Sciences TRANSCRIPT

Empowered Patient Podcast

Sarah Smith, Qualitative Specialist and Global Behavioral Science Strategy Lead at Oracle Life Sciences, is focused on the critical role of behavioral science in improving recruitment and retention in clinical trials.  Oracle Life Sciences is working to address historical underrepresentation in clinical trials by combining behavioral insights with integrated technologies to identify at-risk populations and understand barriers to participation. Using nudges to encourage trial participation, conducting decentralized trials, and applying AI to reshape patient engagement are strong tools for...

info_outline
Using Behavioral Science to Expand Clinical Trial Participation and Patient Engagement with Sarah Smith Oracle Life Sciences show art Using Behavioral Science to Expand Clinical Trial Participation and Patient Engagement with Sarah Smith Oracle Life Sciences

Empowered Patient Podcast

Sarah Smith, Qualitative Specialist and Global Behavioral Science Strategy Lead at Oracle Life Sciences, is focused on the critical role of behavioral science in improving recruitment and retention in clinical trials.  Oracle Life Sciences is working to address historical underrepresentation in clinical trials by combining behavioral insights with integrated technologies to identify at-risk populations and understand barriers to participation. Using nudges to encourage trial participation, conducting decentralized trials, and applying AI to reshape patient engagement are strong tools for...

info_outline
Using Deep Brain Stimulation for Treatment-Resistant Depression with Dr. Josh Eloge Connected Neuroscience TRANSCRIPT show art Using Deep Brain Stimulation for Treatment-Resistant Depression with Dr. Josh Eloge Connected Neuroscience TRANSCRIPT

Empowered Patient Podcast

Dr. Josh Eloge, Associate Director for the Woman's Board Treatment Research Center, Assistant Professor of Psychiatry and Behavioral Sciences at the Rush University Medical Center, and Founder of Connected Neuroscience has a focus on treatment-resistant depression which is defined as depression that is not relieved by at least two first-line medications. Research has identified that TRD is associated with hyperactivity in a specific brain region, shifting attention from a chemical view of depression to a neurobiological one.  Research on deep-brain stimulation and implantable technology...

info_outline
Using Deep Brain Stimulation for Treatment-Resistant Depression with Dr. Josh Eloge Connected Neuroscience show art Using Deep Brain Stimulation for Treatment-Resistant Depression with Dr. Josh Eloge Connected Neuroscience

Empowered Patient Podcast

Dr. Josh Eloge, Associate Director for the Woman's Board Treatment Research Center, Assistant Professor of Psychiatry and Behavioral Sciences at the Rush University Medical Center, and Founder of Connected Neuroscience has a focus on treatment-resistant depression which is defined as depression that is not relieved by at least two first-line medications. Research has identified that TRD is associated with hyperactivity in a specific brain region, shifting attention from a chemical view of depression to a neurobiological one.  Research on deep-brain stimulation and implantable technology...

info_outline
Addressing Health Disparities Through Workforce Diversity and Improved Access to Clinical Trials with Dr. Eugene Manley STEMM & Cancer Health Equity Foundation TRANSCRIPT show art Addressing Health Disparities Through Workforce Diversity and Improved Access to Clinical Trials with Dr. Eugene Manley STEMM & Cancer Health Equity Foundation TRANSCRIPT

Empowered Patient Podcast

Dr. Eugene Manley, biomedical scientist turned social impact leader and Founder and CEO of the STEMM & Cancer Health Equity Foundation,  is focused on increasing STEMM workforce diversity and improving outcomes for underserved cancer patients. He highlights the lack of diversity in foundational lung cancer research and the need to expand the number of cell lines being included to develop more effective therapies. Eugene also raises concerns about barriers to clinical trial participation and the need to engage local community partners and AI to raise awareness and improve...

info_outline
Addressing Health Disparities Through Workforce Diversity and Improved Access to Clinical Trials with Dr. Eugene Manley STEMM & Cancer Health Equity Foundation show art Addressing Health Disparities Through Workforce Diversity and Improved Access to Clinical Trials with Dr. Eugene Manley STEMM & Cancer Health Equity Foundation

Empowered Patient Podcast

Dr. Eugene Manley, biomedical scientist turned social impact leader and Founder and CEO of the STEMM & Cancer Health Equity Foundation,  is focused on increasing STEMM workforce diversity and improving outcomes for underserved cancer patients. He highlights the lack of diversity in foundational lung cancer research and the need to expand the number of cell lines being included to develop more effective therapies. Eugene also raises concerns about barriers to clinical trial participation and the need to engage local community partners and AI to raise awareness and improve...

info_outline
 
More Episodes

Ben Backus, Chief Science Officer, and James Blaha, CEO and Founder of Vivid Vision, discuss their work addressing binocular dysfunctions and improving visual field testing. Their innovative visual test uses a consumer-grade VR headset to deliver a gamified, less stressful, more engaging experience for patients, encouraging longer, more frequent testing. This approach also improves dataset precision and overcomes barriers in clinical trials for new therapeutics for diseases such as glaucoma and macular degeneration, potentially accelerating the development of vision-saving treatments.

Ben explains, "Vivid Vision addresses two conditions. One of them is binocular dysfunctions, which include conditions like amblyopia, strabismus, and convergence insufficiency. And the other one that we're really focusing strongly on now is visual field testing, which is especially important to use for monitoring people who have glaucoma. It also gets used for screening tests for glaucoma, and it's an especially important part of getting new therapeutics approved for any medication that is going to try to preserve your sight. That includes macular degeneration, a particular flavor of macular degeneration, degeneration called geographic atrophy, inherited retinal diseases, diabetic retinopathy, and stroke. It's the visual field test that we are putting the majority of our effort into, but we still also treat binocular dysfunction."  

James elaborates, "I originally got started, I guess, because I grew up with some binocular vision disorders. I had a lazy eye and a crossed eye, also known as strabismus and amblyopia. And I had kind of the traditional experience as a kid where I was not cooperative with the treatments, wearing my eye patch, and doing eye exercises, and that sort of thing. And I wasn't successfully treated as a kid. About 60% of the time, that's the case in the US, where kids are not successfully treated for conditions. Then, when I was older, in my mid-twenties, I got interested in this topic through a TED talk by a neuroscientist, Sue Barry. That ultimately caused me to make the first prototypes, and I was able to gain 3D vision depth perception from some of those first prototypes. And that's ultimately what caused us to start the company."

#VividVision #VRHealthcare #EyeHealth #MedicalTechnology #DigitalHealth #VisionTesting #Innovation #Glaucoma #MacularDegeneration #Amblyopia #HealthTech #VirtualReality #PatientCare #EarlyDetection #ClinicalTrials

seevividly.com

Download the transcript here

Vivid